Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|August 2, 2016
- Pharmaceutical Technology-08-02-2016
- Volume 40
- Issue 8
Custom Lump Breaker for Effective Sifting
The rotary lump breaker unit from Ajax Equipment comprises a screw feeder with sifting screens and collecting conveyor for a gentle lump breaking action on pharmaceutical powders.
The rotary lump breaker unit from Ajax Equipment comprises a screw feeder with sifting screens and collecting conveyor for a gentle lump breaking action on pharmaceutical powders. Powder agglomerates enter the highly polished sifter from a feeding screw, where a rotating paddle forces the powder through the sifter grille and into a collecting conveyor. The sealed unit provides an effective sifting action and controlled feed for powders. The powder sifter is constructed from Hastelloy and is mounted on a portable frame. It is designed for clean-in-place with access nozzles situated throughout the unit.
Articles in this issue
about 10 years ago
Designing Flexible Aseptic Containment Systemsabout 10 years ago
Using 3D Printing for Solid-Dosage Drugsabout 10 years ago
One Strategy for Updating an Aging Facilityabout 10 years ago
Downstream Processing Continues to Worry CMOsabout 10 years ago
Quality Manufacturing Key to Stemming Drug Shortagesabout 10 years ago
New Equipment Meets Need for Innovation in Pharma Manufacturingabout 10 years ago
Evaluating Technology and Innovation in Biopharmaceutical Manufacturingabout 10 years ago
FDA and the Emerging Technology of 3D Printingabout 10 years ago
Measuring Equipment and Manufacturing Trendsabout 10 years ago
Manufacturing and Distribution Boundaries BlurRelated to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: E&L Standards Harmonization
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5